Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

References

• Goral S. The three-signal hypothesis of lymphocyte activation/targets for immunosuppression. Dial Transplant. 2011;40(1):14–17. doi:10.1002/dat.20527.
   Google Scholar
• Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013;37(4):273–83. doi:10.1152/advan.00066.2013.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin Chim Acta. 2012;413(17–18):1338–49. doi:10.1016/j.cca.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009;206(7):1525–34. doi:10.1084/jem.20090504.
   PubMed Web of Science ®Google Scholar
• Kwok WW, Tan V, Gillette L, Littell CT, Soltis Ma, LaFond RB, Yang J, James EA, DeLong JH. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J Immunol (Baltimore, Md: 1950). 2012;188(6):2537–44.doi:10.4049/jimmunol.1102190.
   Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22(1):745–63. doi:10.1146/annurev.immunol.22.012703.104702.
   PubMed Web of Science ®Google Scholar
• Fernandez L, Bustos RH, Zapata C, Garcia J, Jauregui E, Ashraf GM. Immunogenicity in protein and peptide based-therapeutics: an overview. Curr Protein Pept Sci. 2018;19(10):958–71. doi:10.2174/1389203718666170828123449.
   PubMed Web of Science ®Google Scholar
• Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2015;43(D1):D423–31. doi:10.1093/nar/gku1161.
   PubMed Web of Science ®Google Scholar
• De Groot A, Cousens L, Mingozzi F, Martin W. Tregitope peptides: the active pharmaceutical ingredient of IVIG?. Clin Dev Immunol. 2013;2013:493138. doi:10.1155/2013/493138.
   PubMedGoogle Scholar
• Bresciani A, Paul S, Schommer N, Dillon MB, Bancroft T, Greenbaum J, Sette A, Nielsen M, Peters B. T-cell recognition is shaped by epitope sequence conservation in the host proteome and microbiome. Immunology. 2016;148(1):34–39. doi:10.1111/imm.12585.
   PubMed Web of Science ®Google Scholar
• Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, Guillaume P, Coukos G, Harari A, Jandus C, et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nat Biotechnol. 2019;37(11):1283–86. doi:10.1038/s41587-019-0289-6.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Olsson N, Wagar LE, Fast E, Liu CL, Muftuoglu Y, Sworder BJ, Diehn M, Levy R, et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat Biotechnol. 2019;37(11):1332–43. doi:10.1038/s41587-019-0280-2.
   PubMed Web of Science ®Google Scholar
• Abelin JG, Harjanto D, Malloy M, Suri P, Colson T, Goulding SP, Creech AL, Serrano LR, Nasir G, Nasrullah Y, et al. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity. 2019;51(4):766–779.e17. doi:10.1016/j.immuni.2019.08.012.
   PubMed Web of Science ®Google Scholar
• Barra C, Ackaert C, Reynisson B, Schockaert J, Jessen LE, Watson M, Jang A, Comtois-Marotte S, Goulet J-P, Pattijn S, et al. Immunopeptidomic data integration to artificial neural networks enhances protein-drug immunogenicity prediction. Front Immunol. 2020;11:1304. doi:10.3389/fimmu.2020.01304.
   PubMed Web of Science ®Google Scholar
• Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8(8):889–906. doi:10.2217/imt-2016-0049.
   PubMed Web of Science ®Google Scholar
• Hogwood CE, Bracewell DG, Smales CM. Measurement and control of host cell proteins (HCPs) in CHO cell bioprocesses. Curr Opin Biotechnol. 2014;30:153–60. doi:10.1016/j.copbio.2014.06.017.
   PubMed Web of Science ®Google Scholar
• Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res. 2016;2016:1298473. doi:10.1155/2016/1298473.
   PubMed Web of Science ®Google Scholar
• Yin L, Chen X, Vicini P, Rup B, Hickling TP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell Immunol. 2015;295(2):118–26. doi:10.1016/j.cellimm.2015.03.002.
   PubMed Web of Science ®Google Scholar
• Morgan H, Tseng SY, Gallais Y, Leineweber M, Buchmann P, Riccardi S, Nabhan M, Lo J, Gani Z, Szely N, et al. Evaluation of in vitro assays to assess the modulation of dendritic cells functions by therapeutic antibodies and aggregates. Front Immunol. 2019;10:1–14. doi:10.3389/fimmu.2019.00601.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109–18. doi:10.1084/jem.179.4.1109.
   PubMed Web of Science ®Google Scholar
• Turbica I, Gallais Y, Gueguen C, Tharinger H, Al Sabbagh C, Gorges R, Gary-Gouy H, Kerdine-ro¨mer S, Pallardy M, Mascarell L, et al. Ectosomes from neutrophil-like cells down-regulate nickel-induced dendritic cell maturation and promote Th2 polarization. J Leukoc Biol. 2015;97(4):737–49. doi:10.1189/jlb.3A0314-132RR.
   PubMed Web of Science ®Google Scholar
• Xue L, Hickling T, Song R, Nowak J, Rup B. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody. Clin Exp Immunol. 2016;183(1):102–13. doi:10.1111/cei.12711.
   PubMed Web of Science ®Google Scholar
• Spindeldreher S, Karle A, Correia E, Tenon M, Gottlieb S, Huber T, Maillere B, Kolbinger F. T cell epitope mapping of secukinumab and ixekizumab in healthy donors. mAbs. 2020;12(1):1707418. doi:10.1080/19420862.2019.1707418.
   PubMed Web of Science ®Google Scholar
• Kropshofer H, Vogt AB, Hämmerling GJ. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acad Sci U S A. 1995;92(18):8313–17. doi:10.1073/pnas.92.18.8313.
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Kubo C, Takahashi A, Muraoka K, Takeiri A, Ito S, Yano M, Mimoto F, Maeda A, Iwayanagi Y, et al. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. mAbs. 2018;10(8):1168–81. doi:10.1080/19420862.2018.1518888.
   PubMed Web of Science ®Google Scholar
• Karle AC. Applying MAPPs assays to assess drug immunogenicity. Front Immunol. 2020;11:1–11. doi:10.3389/fimmu.2020.00698.
   PubMed Web of Science ®Google Scholar
• Steiner G, Marban-Doran C, Langer J, Pimenova T, Duran-Pacheco G, Sauter D, Langenkamp A, Solier C, Singer T, Bray-French K, et al. Enabling routine MHC-II-associated peptide proteomics for risk assessment of drug-induced immunogenicity. J Proteome Res. 2020;19(9):3792–806. doi:10.1021/acs.jproteome.0c00309.
   PubMed Web of Science ®Google Scholar
• Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjær SB, Pascal V, León IR, Gudme CN, Buus S, et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci Transl Med. 2017;9(372):1–12. doi:10.1126/scitranslmed.aag1286.
   Web of Science ®Google Scholar
• Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, Sette A. Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol (Baltimore, Md: 1950). 2010;184(5):2492–503. doi:10.4049/jimmunol.0903655.
   PubMed Web of Science ®Google Scholar
• Hrdinová J, Verbij FC, Kaijen PHP, Hartholt RB, Van Alphen F, Lardy N, Ten Brinke A, Vanhoorelbeke K, Hindocha PJ, De Groot AS, et al. Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ. Haematologica. 2018;103(6):1083–92. doi:10.3324/haematol.2017.179119.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Moore E, Voic H, Sidney J, Phillips E, Jadi R, Mallal S, De Silva AD, De Silva AM, Peters B, et al. Characterization of magnitude and antigen specificity of HLA-DP, DQ, and DRB3/4/5 restricted DENV-specific CD4+ T cell responses. Front Immunol. 2019;10:1568. doi:10.3389/fimmu.2019.01568.
   PubMed Web of Science ®Google Scholar
• Jankowski W, Park Y, McGill J, Maraskovsky E, Hofmann M, Diego VP, Luu BW, Howard TE, Kellerman R, Key NS, et al. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Adv. 2019;3(9):1429–40. doi:10.1182/bloodadvances.2018030452.
   PubMed Web of Science ®Google Scholar
• Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, Pallardy M, Carbonnel F, Spindeldreher S, Mariette X, et al. Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors. Front Immunol. 2017;8:500. doi:10.3389/fimmu.2017.00500.
   PubMed Web of Science ®Google Scholar
• Deenadayalan A, Maddineni P, Raja A. Comparison of whole blood and PBMC assays for T-cell functional analysis. BMC Res Notes. 2013;6(1):120. doi:10.1186/1756-0500-6-120.
   PubMedGoogle Scholar
• Jawa V, Joubert MK, Zhang Q, Deshpande M, Hapuarachchi S, Hall MP, Flynn GC. Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics. AAPS J. 2016;18(6):1439–52. doi:10.1208/s12248-016-9948-4.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, Baker MP, Herskovitz J, Goletz TJ, Zhou L, et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS ONE. 2016;11(8):1–22. doi:10.1371/journal.pone.0159328.
   Web of Science ®Google Scholar
• Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006;55(9):2588–94. doi:10.2337/db05-1378.
   PubMed Web of Science ®Google Scholar
• Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol. 2010;137(1):5–14. doi:10.1016/j.clim.2010.06.018.
   PubMed Web of Science ®Google Scholar
• Meunier S, Menier C, Marcon E, Lacroix-Desmazes S, Maillère B. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. Blood Adv. 2017;1(21):1842–47. doi:10.1182/bloodadvances.2017008706.
   PubMedGoogle Scholar
• Moser JM, Sassano ER, Leistritz DC, Eatrides JM, Phogat S, Koff W, Drake DR. Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells. J Immunol Methods. 2010;353(1–2):8–19. doi:10.1016/j.jim.2009.11.006.
   PubMed Web of Science ®Google Scholar
• Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, Bohle B. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol. 2005;116(1):213–19. doi:10.1016/j.jaci.2005.04.019.
   PubMed Web of Science ®Google Scholar
• Henrickson SE, Mempel TR, Mazo IB, Liu B, Artyomov MN, Zheng H, Peixoto A, Flynn MP, Senman B, Junt T, et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol. 2008;9(3):282–91. doi:10.1038/ni1559.
   PubMed Web of Science ®Google Scholar
• Rothoeft T, Gonschorek A, Bartz H, Anhenn O, Schauer U. Antigen dose, type of antigen-presenting cell and time of differentiation contribute to the T helper 1/T helper 2 polarization of naive T cells. Immunology. 2003;110(4):430–39. doi:10.1111/j.1365-2567.2003.01758.x.
   PubMed Web of Science ®Google Scholar
• Wölfl M, Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc. 2014;9(4):950–66. doi:10.1038/nprot.2014.064.
   PubMed Web of Science ®Google Scholar
• Castelli FA, Leleu M, Pouvelle-Moratille S, Farci S, Zarour HM, Andrieu M, Auriault C, Ménez A, Georges B, Maillere B, et al. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins. Eur J Immunol. 2007;37(6):1513–23. doi:10.1002/eji.200636783.
   PubMed Web of Science ®Google Scholar
• Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J off Publ Fed Am Soc Exp Biol. 2011;25(6):2040–48. doi:10.1096/fj.10-173872.
   PubMed Web of Science ®Google Scholar
• Von Baehr V, Mayer W, Liebenthal C, Von Baehr R, Bieger W, Volk HD. Improving the in vitro antigen specific T cell proliferation assay: the use of interferon-alpha to elicit antigen specific stimulation and decrease bystander proliferation. J Immunol Methods. 2001;251(1–2):63–71. doi:10.1016/S0022-1759(01)00297-6.
   PubMed Web of Science ®Google Scholar
• Schultz HS, Reedtz-Runge SL, Bäckström BT, Lamberth K, Pedersen CR, Kvarnhammar AM, Akatsuka Y. Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell: PBMC assay. PloS One. 2017;12(5):e0178544. doi:10.1371/journal.pone.0178544.
   PubMed Web of Science ®Google Scholar
• Navarrete MA, Bertinetti-Lapatki C, Michelfelder I, Veelken H. Usage of standardized antigen-presenting cells improves ELISpot performance for complex protein antigens. J Immunol Methods. 2013;391(1–2):146–53. doi:10.1016/j.jim.2013.03.004.
   PubMed Web of Science ®Google Scholar
• Möller JF, Möller B, Wiedenmann B, Berg T, Schott E. CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection. J Viral Hepat. 2011;18(7):e341–9. doi:10.1111/j.1365-2893.2010.01430.x.
   PubMed Web of Science ®Google Scholar
• Kutscher S, Dembek CJ, Deckert S, Russo C, Körber N, Bogner JR, Geisler F, Umgelter A, Neuenhahn M, Albrecht J, et al. Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials. PloS One. 2013;8(10):e76215. doi:10.1371/journal.pone.0076215.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012;287(30):25266–79. doi:10.1074/jbc.M111.330902.
   PubMed Web of Science ®Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. mAbs. 2016;8(3):536–50. doi:10.1080/19420862.2015.1136761.
   PubMed Web of Science ®Google Scholar
• Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJP, Ottensmeier C, Van Der Burg SH, Britten CM, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother CII. 2010;59(10):1489–501. doi:10.1007/s00262-010-0875-4.
   PubMed Web of Science ®Google Scholar
• Ten BA, Marek-Trzonkowska N, Mansilla MJ, Turksma AW, Piekarska K, Iwaszkiewicz-Grzes D, Passerini L, Locafaro G, Puñet-Ortiz J, Van Ham SM, et al. Monitoring T-Cell responses in translational studies: optimization of dye-based proliferation assay for evaluation of antigen-specific responses. Front Immunol. 2017;8:1870. doi:10.3389/fimmu.2017.01870.
   PubMed Web of Science ®Google Scholar
• Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1(9):751–61. doi:10.1016/S1074-7613(94)80017-0.
   PubMed Web of Science ®Google Scholar
• Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002;260(1–2):157–72. doi:10.1016/S0022-1759(01)00535-X.
   PubMed Web of Science ®Google Scholar
• Grenga I, Donahue RN, Lepone LM, Richards J, Schlom J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunol. 2016;5(5):e83. doi:10.1038/cti.2016.27.
   PubMedGoogle Scholar
• Dalkas GA, Rooman M. SEPIa, a knowledge-driven algorithm for predicting conformational B-cell epitopes from the amino acid sequence. BMC Bioinform. 2017;18(1):95. doi:10.1186/s12859-017-1528-9.
   PubMedGoogle Scholar
• Hwai H, Chen YY, Tzeng SJ. B-cell ELISpot assay to quantify antigen-specific antibody-secreting cells in human peripheral blood mononuclear cells. Methods Mol Biol. 2018;1808:133–41.
   PubMedGoogle Scholar
• Liao K, Derbyshire S, Wang K-F, Caucci C, Tang S, Holland C, Loercher A, Gunn GR. Detection of memory B activity against a therapeutic protein in treatment-naïve subjects. AAPS J. 2018;20(3):51. doi:10.1208/s12248-018-0198-5.
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler H-C, Joubert MK, Jawa V, Narhi LO. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 2016;105(5):1567–75. doi:10.1016/j.xphs.2016.02.031.
   PubMed Web of Science ®Google Scholar
• Mangalam AK, Rajagopalan G, Taneja V, David CS. HLA class II transgenic mice mimic human inflammatory diseases. Adv Immunol. 2008;97:65–147.
   PubMed Web of Science ®Google Scholar
• Chen WC, Murawsky CM. Strategies for generating diverse antibody repertoires using transgenic animals expressing human antibodies. Front Immunol. 2018;9:460.doi: 10.3389/fimmu.2018.00460.
   Google Scholar
• Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, Hokom M, Goletz TJ, et al. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J Pharm Sci. 2013;102(10):3545–55. doi:10.1002/jps.23663.
   PubMed Web of Science ®Google Scholar
• Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, Kiialainen A, Koulov A, Boll B, Weiser T, et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 2015;32(7):2344–59. doi:10.1007/s11095-015-1627-0.
   PubMed Web of Science ®Google Scholar
• Boll B, Bessa J, Folzer E, Ríos Quiroz A, Schmidt R, Bulau P, Finkler C, Mahler H-C, Huwyler J, Iglesias A, et al. Extensive chemical modifications in the primary protein structure of IgG1 subvisible particles are necessary for breaking immune tolerance. Mol Pharm. 2017;14(4):1292–99. doi:10.1021/acs.molpharmaceut.6b00816.
   PubMedGoogle Scholar
• Steinitz KN, Van Helden PM, Binder B, Wraith DC, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Weiller M, Lubich C, et al. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood. 2012;119(17):4073–82. doi:10.1182/blood-2011-08-374645.
   PubMed Web of Science ®Google Scholar
• Van Helden PM, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Schiviz AN, Weiller M, Antoine G, Turecek PL, Muchitsch EM, et al. Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood. 2011;118(13):3698–707. doi:10.1182/blood-2010-11-316521.
   PubMed Web of Science ®Google Scholar
• Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci. 2019;108(5):1637–54. doi:10.1016/j.xphs.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Walsh NC, Kenney LL, Jangalwe S, Aryee K-E, Greiner DL, Brehm MA, Shultz LD. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017;12(1):187–215. doi:10.1146/annurev-pathol-052016-100332.
   PubMedGoogle Scholar
• Yong KSM, Her Z, Chen Q. Humanized mice as unique tools for human-specific studies. Arch Immunol Ther Exp (Warsz). 2018;66(4):245–66. doi:10.1007/s00005-018-0506-x.
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011;481(7379):81–84. doi:10.1038/nature10660.
   PubMed Web of Science ®Google Scholar
• Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, Shin H-S, Brooks SF, Knight HL, Eichbaum Q, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol. 2009;83(14):7305–21. doi:10.1128/JVI.02207-08.
   PubMed Web of Science ®Google Scholar
• Choudhary SK, Rezk NL, Ince WL, Cheema M, Zhang L, Su L, Swanstrom R, Kashuba AD, Margolis DM. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol. 2009;83:8254–58.
   PubMed Web of Science ®Google Scholar
• Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16. doi:10.1371/journal.pmed.0050016.
   PubMed Web of Science ®Google Scholar
• Frias-Staheli N, Dorner M, Marukian S, Billerbeck E, Labitt RN, Rice CM, Ploss A. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J Virol. 2014;88(4):2205–18. doi:10.1128/JVI.03085-13.
   PubMed Web of Science ®Google Scholar
• Greenblatt MB, Vrbanac V, Tivey T, Tsang K, Tager AM, Aliprantis AO, Stoddart Ca. Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PloS One. 2012;7(9):e44664. doi:10.1371/journal.pone.0044664.
   PubMed Web of Science ®Google Scholar
• Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, Follenzi A, Goldstein H. Inhibition ofIn VivoHIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing Anti-HIV antibody. J Virol. 2010;84(13):6645–53. doi:10.1128/JVI.02339-09.
   PubMed Web of Science ®Google Scholar
• Sun C-M, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007;204(8):1775–85. doi:10.1084/jem.20070602.
   PubMed Web of Science ®Google Scholar
• Legrand N, Huntington ND, Nagasawa M, Bakker AQ, Schotte R, Strick-Marchand H, De Geus SJ, Pouw SM, Böhne M, Voordouw A, et al. Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proc Nat Acad Sci. 2011;108(32):13224–29. doi:10.1073/pnas.1101398108.
   PubMed Web of Science ®Google Scholar
• Li Y, Masse-Ranson G, Garcia Z, Bruel T, Kök A, Strick-Marchand H, Jouvion G, Serafini N, Lim AI, Dusseaux M, et al. A human immune system mouse model with robust lymph node development. Nat Methods. 2018;15(8):623–30. doi:10.1038/s41592-018-0071-6.
   PubMed Web of Science ®Google Scholar
• Chen Q, He F, Kwang J, Chan JKY, Chen J. GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J Immunol. 2012;189(11):5223–29. doi:10.4049/jimmunol.1201789.
   PubMed Web of Science ®Google Scholar
• Gunawan M, Her Z, Liu M, Tan SY, Chan XY, Tan WWS, Dharmaraaja S, Fan Y, Ong CB, Loh E, et al. A novel human systemic lupus erythematosus model in humanised mice. Sci Rep. 2017;7(1):16642. doi:10.1038/s41598-017-16999-7.
   PubMedGoogle Scholar
• Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005;106(5):1565–73. doi:10.1182/blood-2005-02-0516.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018;67(10):1845–54. doi:10.1136/gutjnl-2017-315201.
   PubMed Web of Science ®Google Scholar
• Chen X, Hickling TP, Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1—theoretical model. CPT Pharmacometrics Syst Pharmacol. 2014;3:133.
   Google Scholar
• Kierzek AM, Hickling TP, Figueroa I, Kalvass JC, Nijsen M, Mohan K, Veldman GM, Yamada A, Sayama H, Yokoo S, et al. A quantitative systems pharmacology consortium approach to managing immunogenicity of therapeutic proteins. CPT Pharmacometrics Syst Pharmacol. 2019;8:773–76.
   PubMedGoogle Scholar
• Yogurtcu ON, Yang H, Chancey C, Forshee RA, Eder AF. Predictive model for Zika virus RNA minipool nucleic acid testing in outbreak scenarios. Transfusion. 2019;59(7):2211–17. doi:10.1111/trf.15296.
   PubMed Web of Science ®Google Scholar
• Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. Clin Exp Immunol. 2015;181(3):385–400. doi:10.1111/cei.12652.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 2016;18(2):311–20. doi:10.1208/s12248-016-9878-1.
   PubMed Web of Science ®Google Scholar
• Diego VP, Luu BW, Hofmann M, Dinh LV, Almeida M, Powell JS, Rajalingam R, Peralta JM, Kumar S, Curran JE, et al. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. J Thromb Haemost. 2020;18(1):201–16. doi:10.1111/jth.14647.
   PubMed Web of Science ®Google Scholar
• Cassotta A, Mikol V, Bertrand T, Pouzieux S, Le Parc J, Ferrari P, Dumas J, Auer M, Deisenhammer F, Gastaldi M, et al. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients. Nat Med. 2019;25(9):1402–07. doi:10.1038/s41591-019-0568-2.
   PubMed Web of Science ®Google Scholar
• Dhanda SK, Karosiene E, Edwards L, Grifoni A, Paul S, Andreatta M, Weiskopf D, Sidney J, Nielsen M, Peters B, et al. Predicting HLA CD4 immunogenicity in human populations. Front Immunol. 2018;9:1369. doi:10.3389/fimmu.2018.01369.
   PubMed Web of Science ®Google Scholar
• Paul S, Grifoni A, Peters B, Sette A. Major histocompatibility complex binding, eluted ligands, and immunogenicity: benchmark testing and predictions. Front Immunol. 2019;10:3151. doi:10.3389/fimmu.2019.03151.
   PubMed Web of Science ®Google Scholar
• Walsh RE, Lannan M, Wen Y, Wang X, Moreland CA, Willency J, Knierman MD, Spindler L, Liu L, Zeng W, et al. Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. mAbs. 2020;12(1):1764829. doi:10.1080/19420862.2020.1764829.
   PubMed Web of Science ®Google Scholar